The Immuno/rAAV network has recently been introduced by the AFM and Genethon.
Its management was entrusted to Professor Olivier Benveniste for the Institute of Myology and Carole Masurier for Genethon. This network aims to develop collaborations between clinicians, immunologists, virologists and veterinarians involved in preclinical and clinical trials using AAV viruses*.
On May 18-19 this network held a meeting in Nantes with the participation of about twenty people from the Institute of Myology, Genethon, the AFM and teams in Nantes and Rouen.
The group gave an overview of this technique in human and animal diseases (dog and larger models), they distributed each person’s role in defining this gene therapy product: vector design, transgene, administration route, dose and vector quality.

* Adeno-associated viruses (AAV) are small DNA viruses, non-pathogenic, existing both in humans and primates. They are very attractive to serve as a vector for gene transfer and have demonstrated their efficiency in numerous gene therapy preclinical studies.
Références :